{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:57:31Z","timestamp":1781611051351,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82360539"],"award-info":[{"award-number":["82360539"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>DEP domain-containing protein 1 (DEPDC1) is essential for cell cycle regulation and is increasingly associated with multiple cancers. Accumulating evidence demonstrates that DEPDC1 is significantly upregulated in tumor tissues than in non-malignant tissues across 31 cancer types. DEPDC1 overexpression has been linked to poor prognostic in many cancers, including ACC, KICH, KIRC, KIRP, LGG, LIHC, LUAD, MESO, PAAD, PCPG, SARC, UCEC, and UVM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, we analyzed the differential expression of DEPDC1 along with the gene expression profiles associated with it. Specifically, we identified differentially expressed genes (DEGs) associated with higher DEPDC1 expression. These DEGs are involved in key signaling pathways related to cell cycle regulation, DNA damage response, and DNA repair mechanisms across various cancers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The findings show that heightened DEPDC1 expression correlates with significantly upregulated DEGs associated with critical signaling pathways, including Hedgehog, Hippo, MAPK, MYC, NF-KB, Notch, p27, p53, PI3K\/AKT, PLK1, RbE2F, TGF-\u03b2, WNT, and MCM across numerous cancers. In addition, elevated DEPDC1 levels positively associate with more TH2 cells, which correlate with poor prognosis. Additionally, a strong relationship was identified between DEPDC1 and genes involved in various immune checkpoints (CD80, CD274, CD276, NRP1, CD160, TNFSF15), chemokines (CXCL8, CXCL5, CXCL10, CCL20, CXCL11, CCL7, CXCL9), chemokine receptor (CCR8, CXCR4, CCR1, CCR3, CXCR6, CCR4, CCR5) genes, and DNA mismatch repair (MMR) processes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings underscore the potential of DEPDC1 as a crucial biomarker in cancer prognosis and the biologic pathways modulation. Future studies are necessary to validate the diagnostic and prognostic implications of DEPDC1, enabling the development of targeted therapeutic interventions targeting this protein, which holds promise for enhancing treatment efficacy in cancer patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40659-025-00643-0","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T01:51:16Z","timestamp":1759888276000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["DEP domain containing 1: a potential oncogenic driver"],"prefix":"10.1186","volume":"58","author":[{"given":"Yi","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiqin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youyou","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"issue":"24","key":"643_CR1","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.21037\/atm-22-5598","volume":"10","author":"B Jia","year":"2022","unstructured":"Jia B, Liu J, Hu X, et al. Pan-cancer analysis of DEPDC1 as a candidate prognostic biomarker and associated with immune infiltration. Ann Transl Med. 2022;10(24):1355.","journal-title":"Ann Transl Med"},{"issue":"5","key":"643_CR2","doi-asserted-by":"publisher","first-page":"518","DOI":"10.3892\/ol.2024.14651","volume":"28","author":"H Danqi Liu","year":"2024","unstructured":"Danqi Liu H, Li J, Ouyang. Roles of DEPDC1 in various types of cancer. Oncol Lett. 2024;28(5):518.","journal-title":"Oncol Lett"},{"issue":"3","key":"643_CR3","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.bbrc.2017.06.105","volume":"490","author":"L Huang","year":"2017","unstructured":"Huang L, Chen K, Cai ZP, et al. DEPDC1 promotes cell proliferation and tumor growth via activation of E2F signaling in prostate cancer. Biochem Biophys Res Commun. 2017;490(3):707\u201312.","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"643_CR4","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41419-024-06913-1","volume":"15","author":"SC Di","year":"2024","unstructured":"Di SC, Chen WJ, Yang W, et al. DEPDC1 as a metabolic target regulates Glycolysis in renal cell carcinoma through AKT\/mTOR\/HIF1alpha pathway. Cell Death Dis. 2024;15(7):533.","journal-title":"Cell Death Dis"},{"issue":"14","key":"643_CR5","doi-asserted-by":"publisher","first-page":"5829","DOI":"10.1158\/0008-5472.CAN-10-0255","volume":"70","author":"Y Harada","year":"2010","unstructured":"Harada Y, Kanehira M, Fujisawa Y, et al. Cell-permeable peptide DEPDC1-ZNF224 interferes with transcriptional repression and oncogenicity in bladder cancer cells. Cancer Res. 2010;70(14):5829\u201339.","journal-title":"Cancer Res"},{"issue":"22","key":"643_CR6","doi-asserted-by":"publisher","first-page":"13303","DOI":"10.1111\/jcmm.15947","volume":"24","author":"W Wang","year":"2020","unstructured":"Wang W, Li A, Han X, et al. DEPDC1 up-regulates RAS expression to inhibit autophagy in lung adenocarcinoma cells. J Cell Mol Med. 2020;24(22):13303\u201313.","journal-title":"J Cell Mol Med"},{"issue":"12","key":"643_CR7","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1002\/cbin.11905","volume":"46","author":"B Zhao","year":"2022","unstructured":"Zhao B, Wang Y, Zhao X, et al. SIRT1 enhances oxaliplatin resistance in colorectal cancer through microRNA-20b-3p\/DEPDC1 axis. Cell Biol Int. 2022;46(12):2107\u201317.","journal-title":"Cell Biol Int"},{"issue":"3","key":"643_CR8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3233\/CBM-201760","volume":"30","author":"Z Gong","year":"2021","unstructured":"Gong Z, Chu H, Chen J, et al. DEPDC1 upregulation promotes cell proliferation and predicts poor prognosis in patients with gastric cancer. Cancer Biomark. 2021;30(3):299\u2013307.","journal-title":"Cancer Biomark"},{"key":"643_CR9","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3389\/fonc.2019.00262","volume":"9","author":"H Zhao","year":"2019","unstructured":"Zhao H, Yu M, Sui L, et al. High expression of DEPDC1 promotes malignant phenotypes of breast cancer cells and predicts poor prognosis in patients with breast cancer. Front Oncol. 2019;9:262.","journal-title":"Front Oncol"},{"issue":"5","key":"643_CR10","doi-asserted-by":"publisher","first-page":"5798","DOI":"10.1002\/cam4.5340","volume":"12","author":"L Shen","year":"2023","unstructured":"Shen L, Li H, Liu R, et al. DEPDC1 as a crucial factor in the progression of human osteosarcoma. Cancer Med. 2023;12(5):5798\u2013808.","journal-title":"Cancer Med"},{"key":"643_CR11","doi-asserted-by":"publisher","first-page":"815998","DOI":"10.3389\/fonc.2022.815998","volume":"12","author":"J Qiu","year":"2022","unstructured":"Qiu J, Tang Y, Liu L, et al. FOXM1 is regulated by DEPDC1 to facilitate development and metastasis of oral squamous cell carcinoma. Front Oncol. 2022;12:815998.","journal-title":"Front Oncol"},{"issue":"3","key":"643_CR12","doi-asserted-by":"publisher","first-page":"182","DOI":"10.5114\/pjp.2023.132223","volume":"74","author":"G Geng","year":"2023","unstructured":"Geng G, Xu Y, Li Q, et al. S100A16 cooperates with DEPDC1 to promote the progression and angiogenesis of nephroblastoma through PI3K\/Akt\/mTOR pathway. Pol J Pathol. 2023;74(3):182\u201393.","journal-title":"Pol J Pathol"},{"issue":"1","key":"643_CR13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10238-025-01572-8","volume":"25","author":"Y Cui","year":"2025","unstructured":"Cui Y, Sun Y, Liang N, et al. YY1-mediated DUXAP8 facilitates HCC progression via modulating DEPDC1 expression. Clin Exp Med. 2025;25(1):65.","journal-title":"Clin Exp Med"},{"issue":"7","key":"643_CR14","doi-asserted-by":"publisher","first-page":"413","DOI":"10.5483\/BMBRep.2015.48.7.036","volume":"48","author":"Y Mi","year":"2015","unstructured":"Mi Y, Zhang C, Bu Y, et al. DEPDC1 is a novel cell cycle related gene that regulates mitotic progression. BMB Rep. 2015;48(7):413\u20138.","journal-title":"BMB Rep"},{"issue":"2","key":"643_CR15","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s11060-017-2457-1","volume":"133","author":"R Kikuchi","year":"2017","unstructured":"Kikuchi R, Sampetrean O, Saya H, et al. Functional analysis of the DEPDC1 oncoantigen in malignant glioma and brain tumor initiating cells. J Neurooncol. 2017;133(2):297\u2013307.","journal-title":"J Neurooncol"},{"key":"643_CR16","doi-asserted-by":"crossref","unstructured":"Zhang L, Du Y, Xu S et al. DEPDC1, negatively regulated by miR-26b, facilitates cell proliferation via the up-regulation of FOXM1 expression in TNBC. Cancer Lett 2019;442:242\u201351.","DOI":"10.1016\/j.canlet.2018.11.003"},{"issue":"1","key":"643_CR17","first-page":"36","volume":"36","author":"Q Wang","year":"2021","unstructured":"Wang Q, Jiang S, Liu J, et al. DEP domain containing 1 promotes Proliferation, Invasion, and Epithelial-Mesenchymal transition in colorectal cancer by enhancing expression of suppressor of zest 12. Cancer Biother Radiopharm. 2021;36(1):36\u201344.","journal-title":"Cancer Biother Radiopharm"},{"key":"643_CR18","doi-asserted-by":"crossref","unstructured":"Geng G, Li Q, Guo X et al. FOXO3a\u2013modulated DEPDC1 promotes malignant progression of nephroblastoma via the Wnt\/\u03b2\u2013catenin signaling pathway. Mol Med Rep. 2022;26(2).","DOI":"10.3892\/mmr.2022.12788"},{"issue":"4","key":"643_CR19","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.21037\/tcr-24-434","volume":"13","author":"C Li","year":"2024","unstructured":"Li C, Huang Y, Yi X, et al. Pan-cancer prognostic model and immune microenvironment analysis of natural killer cell-related genes. Transl Cancer Res. 2024;13(4):1936\u201353.","journal-title":"Transl Cancer Res"},{"issue":"1","key":"643_CR20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/cas.13867","volume":"110","author":"F Di Qu","year":"2019","unstructured":"Di Qu F, Cui D, Lu, et al. DEP domain containing 1 predicts prognosis of hepatocellular carcinoma patients and regulates tumor proliferation and metastasis. Cancer Sci. 2019;110(1):157\u201365.","journal-title":"Cancer Sci"},{"key":"643_CR21","doi-asserted-by":"publisher","first-page":"664791","DOI":"10.3389\/fcell.2021.664791","volume":"9","author":"Y Li","year":"2021","unstructured":"Li Y, Tian Y, Zhong W, et al. Artemisia argyi essential oil inhibits hepatocellular carcinoma metastasis via suppression of DEPDC1 dependent Wnt\/beta-Catenin signaling pathway. Front Cell Dev Biol. 2021;9:664791.","journal-title":"Front Cell Dev Biol"},{"issue":"Pt 1","key":"643_CR22","doi-asserted-by":"publisher","first-page":"133594","DOI":"10.1016\/j.ijbiomac.2024.133594","volume":"275","author":"M Lv","year":"2024","unstructured":"Lv M, Li X, Zheng C, et al. Exosomal miR-130b-3p suppresses metastasis of non-small cell lung cancer cells by targeting DEPDC1 via TGF-beta signaling pathway. Int J Biol Macromol. 2024;275(Pt 1):133594.","journal-title":"Int J Biol Macromol"},{"issue":"6","key":"643_CR23","first-page":"1233","volume":"164","author":"CLM PaluckaAK","year":"2016","unstructured":"PaluckaAK CLM. Basis Oncoimmunology Cell. 2016;164(6):1233\u201347.","journal-title":"Basis Oncoimmunology Cell"},{"issue":"1","key":"643_CR24","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41698-024-00653-3","volume":"8","author":"P Thomas Freitag","year":"2024","unstructured":"Thomas Freitag P, Kaps J, Ramtke, et al. Combined Inhibition of EZH2 and CDK4\/6 perturbs Endoplasmic reticulum-mitochondrial homeostasis and increases antitumor activity against glioblastoma. NPJ Precis Oncol. 2024;8(1):156.","journal-title":"NPJ Precis Oncol"}],"container-title":["Biological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40659-025-00643-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40659-025-00643-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40659-025-00643-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:48:55Z","timestamp":1781610535000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40659-025-00643-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["643"],"URL":"https:\/\/doi.org\/10.1186\/s40659-025-00643-0","relation":{},"ISSN":["0717-6287"],"issn-type":[{"value":"0717-6287","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"assertion":[{"value":"26 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}